Inventiva announces participation at several investors conferences in May and June 2022
Daix (France), Long Island City (New York, United States), May 23, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the Company’s leadership will participate in two upcoming investors conferences in May and June 2022.
The events details are as follows:
|Conference n°1:||H.C. Wainwright Annual Global Life Sciences Conference|
|Event type:||One-on-one meetings and fireside chat|
|Fireside date:||Tuesday, May 24, 2022, at 11:00-11:30 am (ET) / 5:00-5:30 pm (CET)|
|Conference n°2:||Jefferies 2022 Global Healthcare Conference|
|Event type:||One-on-one meetings and fireside chat|
|Fireside date:||Thursday, June 9, 2022, at 11:00-11:25 am (ET) / 5:00-5:25 pm (CET)|
The link of Jefferies 2022 Global Healthcare Conference will be available on Inventiva’s website in the “Investors – Investor Presentations” section.
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH and other diseases with significant unmet medical needs. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.
The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORg inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.
VP of Global External Affairs
+1 240 620 9175
Laurence Frost /
Tristan Roquet Montegon /
+33 1 53 96 83 83
|Westwicke, an ICR Company|
Patricia L. Bank
+1 415 513 1284
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Monthly information related to total number of voting rights and shares composing the share capital _June 30, 2022.7.7.2022 18:00:00 CEST | Press release
Monthly information related to total number of voting rights and shares composing the share capital _June 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut(1) voting rights Total of net (2) voting rights December 31, 202131 018 55332 518 33932 515 839January 31, 202231 018 55332 518 33932 515 839February 28, 202231 018 55332 518 54732 516 047March 31, 202231 018 55332 518 54732 516 047April 30, 202231 018 55332 518 54732 516 047May 31, 202231 018 55332 518 54732 516 047June 30, 202231 018 55332 520 10732 517 607 (1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of g
KBC Group: KBC completes acquisition of Raiffeisen Bank International's Bulgarian operations7.7.2022 17:45:00 CEST | Press release
Press Release Outside trading hours – Regulated information* Brussels, Sofia, 7 July 2022 (5.45 p.m. CEST) KBC completes acquisition of Raiffeisen Bank International's Bulgarian operations Today, KBC Bank and Raiffeisen Bank International (‘RBI’) completed the deal announced on 15 November 2021 concerning the acquisition of 100% of the shares of Raiffeisenbank (Bulgaria) EAD, which is responsible for the banking operations of RBI in Bulgaria. The transaction also includes Raiffeisenbank Bulgaria’s fully owned subsidiaries Raiffeisen Leasing Bulgaria, Raiffeisen Asset Management (Bulgaria), Raiffeisen Insurance Broker and Raiffeisen Service. The acquisition, worth a total of 1 009 million euros paid in cash, reflects the quality of the Raiffeisen franchise in Bulgaria and the potential for synergy. The transaction will have a capital impact of around -1 pp on KBC Group’s CET1 in 3Q2022. Raiffeisenbank (Bulgaria) has systematically developed its banking activities since entering the mark
Volta Finance Limited - Dividend Declaration7.7.2022 17:12:32 CEST | Press release
Volta FinanceLimited (VTA/VTAS) Dividend Declaration NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 7 July 2022 Volta Finance Limited ("the Company") hereby announces a second interim dividend for the financial year commencing 1 August 2021. The Company announces that it has declared a quarterly interim dividend of €0.13 per share payable on 28 July 2022 amounting to approximately €4.75 million, equating approximately to an annualised 8% of net asset value. The ex-dividend date is 14 July 2022 with a record date of 15 July 2022. The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling. Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling. Such instructions may be given to Computershare eith
Maha Energy AB har underrättats om att kontrakterad borrigg i Oman har dragits tillbaka7.7.2022 15:45:00 CEST | Pressemelding
Maha Energy AB (publ) har underrättats av Global Business Services (“GBS”) att den kontrakterade borriggen GBS-1 (tidigare OGI-4) inte längre kommer att vara tillgänglig för Maha Energy i Oman. Detta innebär att den planerade borrstarten av de första sex brunnarna på Mafraqfältet försenas. GBS har meddelat Maha Energy att de inte kan leverera borriggen GBS-1 (tidigare OGI-4) främst på grund av tekniska brister som upptäckts under inspektioner strax innan mobiliseringen. Maha arbetar nu på att hitta alternativa lösningar, men detta innebär att borrningen av de sex brunnarna på Mafraq kommer att försenas. En reviderad tidplan kommer att meddelas så snart som ytterligare information finns tillgänglig. ”Då vi arbetat väldigt hårt för att få allt på plats och starta borrningarna innan den sista juni är vi mycket besvikna över att GBS nu beslutat att inte leverera den kontrakterade borriggen i sista minuten. Men eftersom borrplatser och all annan borrutrustning nu står klart så är vi redo fö
Maha Energy AB has been notified that contracted drilling rig has been withdrawn in Oman7.7.2022 15:45:00 CEST | Press release
Maha Energy AB (publ) has been notified by Global Business Services (“GBS”) that the contracted GBS-1 (formerly OGI-4) drilling rig will no longer be available for Maha Energy in Oman. This means that the planned start of the drilling of the six first wells on the Mafraq field will be delayed. GBS has notified Maha Energy that they are unable to deliver the drilling rig GBS-1 (formerly OGI-4) primarily due to technical deficiencies uncovered during pre-mobilisation inspections. Maha is now evaluating alternative options, but this means that the drilling of the six wells on Mafraq will be delayed. A revised schedule will be announced as soon as further information is available. Jonas Lindvall, CEO at Maha comments: “We have been working hard to ensure all material and equipment were available for a June 30 spud, so it is very disappointing that GBS has decided to withdraw the contracted drilling rig this late in the game. Everything else is in place so once we find a replacement drillin